Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993026 | 1.00 | DPP4 (0.38) | DPP4DPP7L3MBTL3L3MBTL1CHRNB4 | |
| SCHEMBL1992870 | 0.79 | KCNA3 (0.47) | L3MBTL3L3MBTL1ALDH1A1OPRL1KCNA3 | |
| SCHEMBL1991909 | 0.77 | KCNH2 (0.44) | L3MBTL1CYP2D6CYP1A2CYP2C9KCNH2 | |
| SCHEMBL1991989 | 0.75 | CYP1A2 (0.55) | ALDH1A1CYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1991987 | 0.75 | CYP1A2 (0.55) | ALDH1A1CYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12137589 | 0.74 | LMNA (0.58) | DPP4DPP7L3MBTL1ALDH1A1CYP2C19 | |
| SCHEMBL622694 | 0.74 | LMNA (0.58) | DPP4DPP7L3MBTL1ALDH1A1CYP2C19 | |
| SCHEMBL627928 | 0.74 | LMNA (0.58) | DPP4DPP7L3MBTL1ALDH1A1CYP2C19 | |
| SCHEMBL3728983 | 0.74 | LMNA (0.58) | DPP4DPP7L3MBTL1ALDH1A1CYP2C19 | |
| SCHEMBL1992677 | 0.74 | CYP1A2 (0.57) | ALDH1A1CYP2D6CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654807-B2 | Toll-like receptor 8 agonists | THE UNIVERSITY OF KANSAS (US) | 2020-05-19 | — | — | US | disclosed |
| US-10471139-B2 | Toll-like receptor agonists | THE UNIVERSITY OF KANSAS (US) | 2019-11-12 | — | — | US | disclosed |
| US-20160347715-A1 | Toll-Like Receptor 8 Agonists | THE UNIVERSITY OF KANSAS | 2016-12-01 | — | — | US | disclosed |
| US-20160229866-A1 | HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS INC. (US) | 2016-08-11 | — | — | US | disclosed |
| EP-3046924-A1 | HEPATITIS C VIRUS INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2016-07-27 | — | — | EP | disclosed |
| US-20160166681-A1 | TOLL-LIKE RECEPTOR AGONISTS | THE UNIVERSITY OF KANSAS | 2016-06-16 | — | — | US | disclosed |
| US-9187496-B2 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| WO-2015042375-A1 | HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2015023958-A1 | TOLL-LIKE RECEPTOR AGONISTS | THE UNIVERSITY OF KANSAS (US) | 2015-02-19 | — | — | WO | disclosed |
| US-20130071352-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8362068-B2 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120252721-A1 | METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20110150827-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071352-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | HAVCR2, CYP3A5, CYP2E1 | DPP4 1564/4885DPP7 759/4885L3MBTL3 3955/4885 |
| US-20160166681-A1 | TOLL-LIKE RECEPTOR AGONISTS | TLR1, TLR7, TLR8 | DPP4 2910/4885DPP7 2169/4885L3MBTL3 3759/4885 |
| US-10654807-B2 | Toll-like receptor 8 agonists | TLR8, TLR7, TLR1 | DPP4 2422/4885DPP7 1851/4885L3MBTL3 3865/4885 |
| US-20110150827-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | HAVCR2, CYP3A5, CYP2E1 | DPP4 1564/4885DPP7 759/4885L3MBTL3 3955/4885 |
| US-20160347715-A1 | Toll-Like Receptor 8 Agonists | TLR8, TLR7, TLR1 | DPP4 2422/4885DPP7 1851/4885L3MBTL3 3865/4885 |
| US-10471139-B2 | Toll-like receptor agonists | TLR1, TLR7, TLR8 | DPP4 2910/4885DPP7 2169/4885L3MBTL3 3759/4885 |
| US-20120252721-A1 | METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR | HAVCR2, CYP3A5, CYP7A1 | DPP4 1301/4885DPP7 441/4885L3MBTL3 2844/4885 |
| US-20160229866-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, LIPC, LDHB | DPP4 1593/4885DPP7 2070/4885L3MBTL3 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.